Crossject Société Anonyme announced the signing of an Australia & New Zealand commercial agreement for ZENEO Midazolam, its innovative rescue treatment of epileptic seizures. Intramuscular Midazolam is the gold standard to treat patients in the case of certain epileptic seizures that represent a life-threatening situation. The current solutions can be challenging for non-healthcare-prof professionals to administer during an emergency.

There is a clear need for a simple and dependable needle-free way to administer an emergency treatment for epilepsy. The simplicity of use of ZENEO®, will afford patients and their caregivers a needle-free injection technology that delivers life-saving medicine in less than 1/10th second. Under the terms of the agreement, AFT will be responsible for all local regulatory and commercial activities.

In exchange for the commercial rights, Crossject shall receive: about EUR 0.5 million (AUD 0.79 million) of premarketing payments from AFT. About EUR 150,000 (AUD 237,000) is due after the signature of the agreement. The remainder consists of development and approval milestones.

Crossject will manufacture and sell the product to AFT at a mid-double-digit percentage of AFT's net selling price to wholesalers, with a minimum floor price per unit. filing for marketing approval to Australia and New Zealand regulatory authorities is expected a few months after filing in Europe. Epilepsy is the fourth most common neurological disorder in the world, affecting roughly 1 in 26 people, according to the Epilepsy Foundation.

The disorder affects people of all genders, races, ethnic backgrounds andages. It causes surges of electrical activity in the brain that can cause recurring seizures. Epilepsy afflicts an estimated 151,000 people in Australia and an estimated 50,000 people in New Zealand.

Crossject SA is developing and will soon market a portfolio of drugs for use in emergency situations (epilepsy, overdose, allergic shock, severe migraine and asthma attack). With its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency medications. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

AFT Pharmaceuticals Limited is a specialty pharmaceutical company operating primarily in Australasia, but with product distribution agreements worldwide. The company's product portfolio includes prescription and over-the-counter medicines to treat a range of conditions, as well as a patented nebulizer.